Media coverage about Axsome Therapeutics (NASDAQ:AXSM) has trended somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Axsome Therapeutics earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.5744411885076 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media headlines that may have impacted Accern’s scoring:
- Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Hot Stock’s Watch List – Nasdaq Journal (nasdaqjournal.com)
- Axsome Therapeutics (AXSM) Downgraded by Zacks Investment Research to Sell (americanbankingnews.com)
- Axsome Therapeutics Presents Scientific Rationale for the Development of AXS-05 at the 20th Annual Meeting of the … – GlobeNewswire (press release) (globenewswire.com)
- Head to Head Survey: Axsome Therapeutics (AXSM) versus GW Pharmaceuticals PLC- (GWPH) (americanbankingnews.com)
- Axsome Therapeutics Presents Scientific Rationale for the Development of AXS-05 at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics (finance.yahoo.com)
Shares of Axsome Therapeutics (NASDAQ AXSM) traded down $0.08 during trading on Wednesday, reaching $2.82. The company’s stock had a trading volume of 151,410 shares, compared to its average volume of 445,013. The firm has a market capitalization of $72.65, a PE ratio of -2.23 and a beta of -0.20. The company has a quick ratio of 2.90, a current ratio of 2.90 and a debt-to-equity ratio of 0.40. Axsome Therapeutics has a 12-month low of $2.45 and a 12-month high of $6.45.
Several analysts recently weighed in on the company. Zacks Investment Research lowered Axsome Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday. ValuEngine raised Axsome Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Finally, Cantor Fitzgerald set a $13.00 price objective on Axsome Therapeutics and gave the stock a “buy” rating in a research report on Friday, December 1st. Two analysts have rated the stock with a sell rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $16.90.
TRADEMARK VIOLATION WARNING: “Axsome Therapeutics (AXSM) Receives Daily News Impact Rating of 0.16” was posted by BBNS and is the property of of BBNS. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://baseballnewssource.com/2018/03/14/axsome-therapeutics-axsm-given-daily-media-impact-rating-of-0-16/1926423.html.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.